Inflammation is increasingly recognized to play a central role in atherosclerosis and coronary artery disease, and peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these potentially modifiable risk markers to prognosis after ischemic stroke is less clear. The proposed study, Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS), is an approved ancillary study to the on-going NINDS-funded Secondary Prevention of
Showing the most recent 10 out of 16 publications